Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZYWPO
ADC Name
WO2021115426A1 ADC-3
Synonyms
WO2021115426A1 ADC 3
   Click to Show/Hide
Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
Drug-to-Antibody Ratio
2.51
Structure
Antibody Name
h1902-11
  Antibody Info 
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2021115426A1 ADC-3 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.36
nM
SK-BR-3 cells
Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
0.83
nM
U-87MG cells
Glioblastoma
Half Maximal Inhibitory Concentration (IC50) 
1.67
nM
SK-BR-3 cells
Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
2.98
nM
U-87MG cells
Glioblastoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.36 nM Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (short reservation).
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.83 nM Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (short reservation).
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.67 nM Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (long reservation).
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 2.98 nM Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description
Conjugate in various concentrations was added to CLDN18.2-expressing cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium (long reservation).
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
References
Ref 1 Anti-claudin antibody-drug conjugate and pharmaceutical use thereof; 2021-06-17.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.